• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development

    11/17/21 8:31:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SRPT alert in real time by email
    • Gilmore O'Neill, M.B., M.M.Sc., will depart the Company and serve in a consulting capacity through March 31, 2022

    CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that, effective immediately, Louise Rodino-Klapac, Ph.D., executive vice president and chief scientific officer, has been named the Company's head of research and development (R&D) and will continue to serve in the role of chief scientific officer. Gilmore O'Neill, M.B., M.M.Sc., who has served as head of R&D since 2018, will leave the Company at the end of November and remain in a consulting capacity until March 31, 2022.

    "Dr. Rodino-Klapac has been central to our efforts around the discovery and development of Sarepta's gene therapy platform and was an early collaborator in the development of RNA-based therapies as a therapeutic option for patients with rare diseases," said Doug Ingram, president and chief executive officer, Sarepta. "Her exceptional command of our core therapeutic platforms in RNA, gene therapy, and gene editing, and the strength of her scientific leadership has been and will be instrumental as Sarepta advances its industry-leading pipeline of genetic medicines.

    "Dr. Rodino-Klapac inherits a strong research and development function. Dr. O'Neill led our research and development function during a period of enormous expansion and multiple successes, including approvals of our second and third RNA-based therapies for Duchenne muscular dystrophy, and the commencement of pivotal trials for our lead candidates in both our next-generation RNA platform and our gene therapy platform," added Mr. Ingram. "On behalf of the entire team, I would like to thank Dr. O'Neill for all of his contributions to Sarepta and to the patient communities we serve."

    About Sarepta Therapeutics

    Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

    Forward-Looking Statements

    This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding the potential benefits related to the announced leadership transition and Sarepta's potential to advance its industry-leading pipeline of genetic medicines.

    These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Known risk factors include, among others: leadership transitions can be inherently difficult to manage and may cause uncertainty or a disruption to Sarepta's business or may increase the likelihood of turnover in other key officers and employees; Sarepta may not be able to execute on its business plans and goals, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its product candidates to market, due to a variety of reasons, many of which may be outside of Sarepta's control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sarepta's product candidates and the COVID-19 pandemic; and those risks identified under the heading "Risk Factors" in Sarepta's most recent Annual Report on Form 10-K for the year ended December 31, 2020, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta which you are encouraged to review.

    Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.

    Internet Posting of Information

    We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

    Source: Sarepta Therapeutics, Inc.

    Investor Contact:

    Ian Estepan, 617-274-4052

    [email protected]

    Media Contact:

    Tracy Sorrentino, 617-301-8566

    [email protected] 



    Primary Logo

    Get the next $SRPT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SRPT

    DatePrice TargetRatingAnalyst
    6/20/2025Outperform → Mkt Perform
    William Blair
    6/18/2025$24.00Buy → Hold
    TD Cowen
    6/17/2025Peer Perform
    Wolfe Research
    6/16/2025Overweight → Equal-Weight
    Morgan Stanley
    6/16/2025Overweight → Neutral
    Cantor Fitzgerald
    6/16/2025Buy → Neutral
    BofA Securities
    6/16/2025$70.00Outperform → Market Perform
    BMO Capital Markets
    6/16/2025$36.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $SRPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

      Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

      7/12/24 4:40:36 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

      For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

      6/20/24 5:24:42 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

      Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

      6/5/24 4:41:31 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Barry Richard exercised 12,350 shares at a strike of $32.63, increasing direct ownership by 0.42% to 2,966,667 units (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      5/19/25 7:32:14 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Barry Richard exercised 20,246 shares at a strike of $19.23, increasing direct ownership by 0.69% to 2,954,317 units (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      5/15/25 7:00:11 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Nicaise Claude exercised 9,746 shares at a strike of $25.18 and sold $248,203 worth of shares (2,491 units at $99.64), increasing direct ownership by 35% to 27,812 units (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      3/13/25 8:00:04 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chambers Michael Andrew bought $4,955,728 worth of shares (37,038 units at $133.80) (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      8/20/24 8:00:04 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barry Richard bought $3,940,500 worth of shares (50,000 units at $78.81) (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      11/6/23 8:00:11 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ingram Douglas S bought $2,001,800 worth of shares (25,225 units at $79.36), increasing direct ownership by 7% to 390,307 units (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      11/6/23 8:00:10 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    SEC Filings

    See more
    • Sarepta Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

      6/6/25 4:30:31 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Sarepta Therapeutics Inc.

      10-Q - Sarepta Therapeutics, Inc. (0000873303) (Filer)

      5/6/25 4:01:26 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Sarepta Therapeutics Inc.

      DEFA14A - Sarepta Therapeutics, Inc. (0000873303) (Filer)

      4/24/25 4:10:03 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors

      - Veteran biopharmaceutical executive from GSK and Eli Lilly brings more than 30 years of experience to Sarepta's Board Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a well-regarded executive with more than 30 years of experience in the pharmaceutical industry. Following Connelly's appointment, Sarepta's Board will comprise nine directors, eight of whom are independent. "Ms. Connelly is a seasoned board leader with extensive operating experience in biopharma and we're pleased to welcome her to the Sarepta Board of Directors as we work to

      9/16/24 8:30:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

      Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a

      7/17/24 8:00:00 AM ET
      $MDXG
      $SAVA
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics Set to Join S&P MidCap 400

      NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For

      5/29/24 5:48:00 PM ET
      $JNJ
      $SPGI
      $SRPT
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance

    $SRPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

      SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

      11/13/24 10:27:59 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sarepta Therapeutics Inc.

      SC 13G - Sarepta Therapeutics, Inc. (0000873303) (Subject)

      2/9/24 6:05:54 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Sarepta Therapeutics Inc. (Amendment)

      SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

      2/14/23 3:23:55 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2025 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 53 individuals hired by Sarepta in the second quarter of 2025. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received, in the aggregate, options to purchase 22,016 shares of Sarepta's common stock, and in the aggregate 317,317 restricted stock units ("RSUs"). The options have an exercise price of $17.10 per share,

      6/30/25 6:26:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

      - The Company is developing an enhanced immunosuppressive regimen in consultation with a panel of multi-disciplinary clinical experts and engaging with regulators - Shipments of ELEVIDYS for infusions in non-ambulatory patients in commercial setting are suspended until enhanced regimen is approved and in place - ENVISION study is paused while seeking a protocol amendment to incorporate additional immunosuppression - Sarepta to host investor call on June 16, 2025, at 8:00 am Eastern time Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only a

      6/15/25 1:00:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta's Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4

      Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy type 2E/R4, has been granted platform technology designation by the U.S. Food & Drug Administration. "This is one of the first programs to receive platform technology designation and an important recognition by FDA of the reproducibility and adaptability of this technology across multiple therapeutic programs," said Louise Rodino-Klapac, Ph.D., chief scientific officer and head of research & development, Sarepta

      6/4/25 9:30:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sarepta Therapeutics downgraded by William Blair

      William Blair downgraded Sarepta Therapeutics from Outperform to Mkt Perform

      6/20/25 7:52:50 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics downgraded by TD Cowen with a new price target

      TD Cowen downgraded Sarepta Therapeutics from Buy to Hold and set a new price target of $24.00

      6/18/25 7:45:18 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Sarepta Therapeutics

      Wolfe Research initiated coverage of Sarepta Therapeutics with a rating of Peer Perform

      6/17/25 7:51:08 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Financials

    Live finance-specific insights

    See more
    • Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

      - The Company is developing an enhanced immunosuppressive regimen in consultation with a panel of multi-disciplinary clinical experts and engaging with regulators - Shipments of ELEVIDYS for infusions in non-ambulatory patients in commercial setting are suspended until enhanced regimen is approved and in place - ENVISION study is paused while seeking a protocol amendment to incorporate additional immunosuppression - Sarepta to host investor call on June 16, 2025, at 8:00 am Eastern time Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only a

      6/15/25 1:00:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

      Net product revenues for the first quarter 2025 totaled $611.5 million, a 70% increase over the same quarter of the prior year ELEVIDYS net product revenue for the first quarter totaled $375.0 million; Royalty revenue from the sales of ELEVIDYS by Roche for the quarter totaled $4.0 million Revised 2025 total net product revenues guidance to $2.3 to $2.6 billion Meaningfully advanced multiple clinical candidates in limb-girdle muscular dystrophy portfolio Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2025. "In the first quarter, we achieved net product revenue of $611.5 mi

      5/6/25 4:05:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

      Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2025 financial results after the Nasdaq Global Market closes on Tuesday, May 6, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2025 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone

      4/22/25 8:30:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care